The survival benefit of surveillance for hepatocellular carcinoma is controversial.
Dr Grace Lai-Hung Wong and colleagues from China examined the survival benefit of hepatocellular carcinoma surveillance in chronic viral hepatitis.
|Median survival of the surveillance group was 88 weeks|
Survivals of patients with hepatocellular carcinoma related to chronic viral hepatitis from the Hepatology Clinic were compared with those referred from other hospitals/clinics.
Lead-time, and length-time biases were adjusted based on tumor volume doubling times.
The researchers found that among 579 patients, 472 patients had hepatocellular carcinoma.
Of these, 17% were referred from the surveillance program.
Hepatocellular carcinoma was smaller, and fewer in numbers in the surveillance group vs the no-surveillance group.
The team found that treatment by surgery, and local ablative therapy were more frequent in the surveillance group than that in the no-surveillance group.
The median survival of the surveillance group was 88 weeks, significantly longer than the 26 weeks in the no-surveillance group.
The adjusted cumulative survival at 2 years was significantly longer in the surveillance group if the tumor volume doubling time was less than 90 days.
Dr Wongs' team concluded, "Hepatocellular carcinoma surveillance can improve the survival of patients with chronic viral Hepatitis B."